文献速递血管炎

大动脉炎起始队列中高发的早期损害独立预测未来死亡率

High prevalent early damage independently predicts future mortality in an inception cohort of Takayasu arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究在大动脉炎起始队列中使用大血管血管炎损害指数(LVVID)评估早期损害及其演变与预后相关性。199例患者中96.5%在入组时即有损害,基线LVVID较高与死亡率增加持续相关,粗HR每分增加1.49(95%CI 1.24-1.81),且1年及末次随访时LVVID较基线显著进展。

要点

  • 199例大动脉炎患者中96.5%在入组时LVVID可记录到损害,最常见为心血管损害。
  • 基线LVVID每增加1分,粗HR 1.49(95%CI 1.24-1.81);每增加一个四分位,粗HR 1.92(95%CI 1.21-3.05)。
  • 1年时LVVID较基线显著进展(3.49±2.01 vs 3.27±1.86,P<0.001),活动性疾病及糖皮质激素或免疫抑制剂使用可预测进展。

核心结论

  • 大多数大动脉炎患者存在可记录的早期损害,且与未来死亡率相关。

研究设计与样本

  • 研究为起始队列研究,纳入199例大动脉炎患者(141例女性,54例儿童起病),在入组3个月内、1年时及至少1年后的末次随访时进行基线LVVID评分。

主要发现

  • 199例患者中192/199(96.5%)在 presentation 时LVVID可记录到损害,最常见为心血管损害;1年时112/114(98.2%)有损害,末次随访时126/130(96.9%)有损害。
  • 活动性疾病、Hata V型或Goel集群1血管造影亚型患者的初始LVVID更高。
  • 基线LVVID较高与死亡率增加持续相关,粗HR每分增加1.49(95%CI 1.24-1.81),每四分位增加1.92(95%CI 1.21-3.05),调整疾病活动度或血管造影亚型后仍相关。
  • 1年时LVVID较基线显著进展(3.49±2.01 vs 3.27±1.86,P<0.001),末次随访时亦显著进展(3.73±2.18 vs 3.28±1.88,P<0.001)。
  • 进展的预测因素包括入组时活动性疾病(OR 2.89)、糖皮质激素使用(OR 3.53)或免疫抑制剂使用(OR 3.52)。

关键数值与推荐

  • 基线LVVID每增加1分,粗HR 1.49(95%CI 1.24-1.81);每增加一个四分位,粗HR 1.92(95%CI 1.21-3.05)。
  • 1年时LVVID 3.49±2.01 vs 基线3.27±1.86(P<0.001);末次随访时3.73±2.18 vs 基线3.28±1.88(P<0.001)。
  • 入组时活动性疾病预测进展的OR 2.89;糖皮质激素使用OR 3.53;免疫抑制剂使用OR 3.52。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to evaluate early damage, and its evolution and prognostic relevance in an inception cohort of patients with Takayasu arteritis (TAK) using the Large Vessel Vasculitis Index of Damage (LVVID). METHODS: Baseline LVVID was scored in an inception cohort of TAK who were within 3 months of cohort entry, at 1 year, and at the last follow-up at or after 1 year. Levels of associations between initial LVVID scores and demographic characteristics, disease activity, and angiographic subtypes were evaluated. Hazard ratios (HRs) for mortality per point/quartile increase in baseline LVVID scores were calculated using Cox proportional hazards regression. Damage evolution from baseline to 1 year or last follow-up was assessed using the paired Student's t test. Pre-treatment predictors of progression were assessed using logistic regression. RESULTS: Of 199 patients (141 females; 54 paediatric-onset), 192/199 (96.5%) had damage (most often cardiovascular) as indicated by the LVVID at presentation, 112/114 (98.2%) at 1 year, and 126/130 (96.9%) at last follow-up. Initial LVVID was greater with active disease, Hata's type V, or Goel's cluster 1 angiographic subtypes. Higher baseline LVVID was consistently associated with increased mortality [crude HR per point increase 1.49 (95% CI 1.24-1.81) or per quartile increase in LVVID 1.92 (1.21-3.05)], despite adjustment for disease activity or angiographic subtype. Significant progression of LVVID was observed at 1 year (3.49 ± 2.01 vs 3.27 ± 1.86, P < 0.001) or at the last follow-up (3.73 ± 2.18 vs 3.28 ± 1.88 P < 0.001), and was predicted by active disease at presentation [ odds ratio (OR) 2.89] and glucocorticoid (OR 3.53) or immunosuppressant use (OR 3.52). CONCLUSION: Most patients with TAK had recordable early damage, which was associated with future mortality.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Misra DP, Rathore U, Qamar T, et al. High prevalent early damage independently predicts future mortality in an inception cohort of Takayasu arteritis. Rheumatology (Oxford). 2026. PMID: 40996329. doi:10.1093/rheumatology/keaf508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。